In summary, this study showed that the bla NDM-1 is present in bacteria of food animal origin, although currently at a very low prevalence. Nevertheless, further monitoring of the presence of the bla NDM-1 gene and other carbapenemase genes in bacteria of animal origin is warranted.
. Schematic representation of the alignment of the sequences of plasmids pNDM-AB (GenBank accession number KC503911) and pNDM-BJ01. Relevant genes with reference to the description of pNDM-BJ01 4 are presented as arrows, with the arrowhead indicating the direction of transcription. Grey shading indicates ≥99.9% nucleotide sequence identity. ORF, open reading frame.
Infection Control, Akershus University Hospital, Oslo, Norway; 6 Division of Medicine and Laboratory Sciences, University of Oslo, Oslo, Norway Sir, The global emergence and dissemination of acquired carbapenemases among Gram-negative bacteria are considered a major public health problem. 1 The dominant carbapenemases include the class A serine b-lactamases (e.g. KPC), the class B metallo-b-lactamases (e.g. NDM, VIM and IMP) and the class D OXA group. 1 The carbapenemase-encoding genes are often located on plasmids along with other resistance genes, resulting in multidrug-resistant, extremely drug-resistant or pan-drug-resistant bacteria. 1 Among the class D b-lactamases, OXA-48-like carbapenemases have increasingly been identified in Enterobacteriaceae with a wide geographical distribution. 2 After the first identification in Turkey, the dissemination of OXA-48-like carbapenemases was mainly identified in North African and Middle Eastern countries. 2 However, a growing number of reports show a global dissemination of OXA-48-like carbapenemases and, in some European countries, OXA-48-like has become the predominant carbapenemase. 3 The OXA-48-like enzymes have limited activity against extendedspectrum cephalosporins, in contrast to other carbapenemases, and the MIC values of carbapenems are often below the clinical breakpoints. 4 This has implications for detection procedures in the laboratory. 4 In the Nordic countries, the emergence of carbapenemase producers has mainly been associated with patient transfer from other countries. 3 In this study, we characterized the first three OXA-48-like producing Enterobacteriaceae from Norway, of which one isolate coproduced NDM-1. The bacterial isolates, two Klebsiella pneumoniae and one Escherichia coli, were submitted by three different laboratories to the National Reference Centre for Detection of Antimicrobial Resistance in Norway, based on reduced susceptibility to carbapenems ( Table 1 ). All three isolates were isolated from patients who had recently been hospitalized or in contact with a hospital abroad in three separate countries (Romania, Morocco and Thailand) ( Table 1) . National guidelines in Norway recommend that patients who have been hospitalized in countries with a known high prevalence of multidrug-resistant Gram-negative bacteria are screened; two of the isolates were obtained from rectal screening samples. The third isolate was associated with a urinary tract infection. Reasons for hospitalization abroad included a traffic accident or heart problems.
Analysis of the b-lactamase content of the isolates using PCRs followed by sequencing, as previously described, 5 -8 or a nucleic acid-based microarray (Check-Points, Wageningen, The Netherlands) revealed that two isolates harboured bla OXA-48 while one isolate contained both the bla OXA-181 variant and bla NDM-1 ( Table 1 ). The coproduction of OXA-181 and NDM-1 has previously been described in K. pneumoniae from the Sultanate of Oman. 9 Further, all isolates also possessed a CTX-M group 1 extendedspectrum b-lactamase ('ESBL'), as is often found in isolates with bla OXA-48 . 2 All isolates were positive for the OXA-1 group, but negative for the OXA-2 group and OXA-9. The isolate that coproduced OXA-181 and NDM-1 showed high-level resistance to all carbapenems, while the two OXA-48-producing isolates were susceptible to both meropenem and imipenem, but resistant to ertapenem according to EUCAST clinical breakpoints (Table 1) . High-level resistance to extended-spectrum cephalosporins was observed in all isolates due to the presence of bla NDM-1 and/or bla CTX-M . Other acquired antimicrobial resistance markers identified by PCR assays 10 included the aac(6 ′ )-Ib-cr variant found in all isolates, as well as qnrB in the OXA-48-positive K. pneumoniae isolate. The OXA-181-and NDM-1-producing isolate was also resistant to colistin, making this isolate an extremely drug-resistant variant. The two K. pneumoniae isolates were sequence typed as sequence type (ST) 405 and ST525, respectively, by multilocus sequence typing (MLST; Table 1 ). ST405 has recently been associated with OXA-48 in Spain. 11 The E. coli isolate was assigned to ST405, a representative ST of the virulent phylogroup D lineage often associated with bla CTX-M-15 . 12 The bla OXA-48 gene has previously been found to be part of the composite transposon Tn1999 and variants thereof. 2 Mapping of the genetic structure surrounding bla OXA-48-like was performed on our isolates using previously described primers. 13 In both OXA-48-producing isolates, IS1999 was found on both ends of bla OXA-48 , where the IS1999 element upstream of bla OXA-48 was interrupted by an IS1R, as described for the Tn1999.2 variant. 2 In the bla OXA-181 -positive isolate, ISEcp1 was identified upstream of bla OXA-181 , as previously described.
2 Conjugation experiments to E. coli J53-2 were successful for both bla OXA-48 isolates (Table 1) . For the bla OXA-181 -carrying isolate, only transconjugants positive for bla CTX-M and negative for bla OXA-181 and bla NDM-1 were obtained. The bla OXA-48 gene has mainly been associated with an 62 kb IncL/M plasmid harbouring conserved backbone genes (repA, traU and parA).
13
Both bla OXA-48 -positive isolates and the corresponding transconjugants were positive for repA, traU and parA by PCR. repA, traU and parA were not detected in the bla OXA-181 isolate. Plasmid analysis using S1 nuclease digestion of total genomic DNA followed by PFGE and Southern blot hybridization 14 with the bla OXA-48 and parA probes revealed that bla OXA-48 was localized on an 50-60 kb plasmid that cohybridized with the parA probe (data not shown). The bla OXA-181 gene was localized on an 200 kb plasmid.
In conclusion, this study further documents the ongoing global dissemination of bla OXA-48-like , as well as the coexistence of bla NDM-1 and bla OXA-181 in a single K. pneumoniae strain. The acquisition of bla OXA-48-like was related to colonization during foreign travel. These observations emphasize the necessity of rigorous screening of relevant patients upon entry after foreign travel, to prevent the further spread of these strains in lowprevalence countries. MEM, meropenem; IPM, imipenem; ETP, ertapenem; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin/tazobactam; GEN, gentamicin; CIP, ciprofloxacin; TGC, tigecycline; CST, colistin; WT, wild-type; TC, transconjugant. a MLST was performed according to the protocols described at the MLST web sites for K. pneumoniae (http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html) and E. coli (http://mlst.ucc.ie/mlst/dbs/Ecoli). b The antimicrobial susceptibility profiles of the isolates were determined using Etests according to the manufacturer's instructions (bioMérieux) and interpreted according to the clinical breakpoints set by EUCAST (http://www.eucast.org/clinical_breakpoints/).
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Sir, Temocillin, a semi-synthetic 6-a-methoxy derivative of ticarcillin, has been shown to be clinically efficacious in infections caused by extended-spectrum b-lactamase (ESBL)-and AmpC-producing Enterobacteriaceae. 1, 2 It is licensed in the UK for bacteraemia, urinary tract infections (UTIs) and lower respiratory tract infections where susceptible Gram-negative bacteria are suspected or confirmed.
Currently, only the BSAC has defined temocillin breakpoints for Enterobacteriaceae (susceptible if MIC ≤8 mg/L for systemic infections and ≤32 mg/L for UTIs). 3 Here, we report a comparison of three temocillin susceptibility testing methodologies [BD Phoenix TM Automated Microbiology System (instrument version 5.15A, software version 6.01A/V5.15A) (Becton Dickinson, Oxford, UK), Etest (AB Biodisk, Solna, Sweden) and broth microdilution (BMD)]. Our data indicate that, whereas the level of agreement for 'susceptible' results is excellent, the Phoenix system overcalls temocillin non-susceptibility.
A total of 281 consecutive clinical Enterobacteriaceae isolates from distinct patients were collected from urine, blood culture, fluid, respiratory and tissue specimens. Isolates comprised Escherichia coli (194), Klebsiella pneumoniae (19), Proteus mirabilis (16), Enterobacter cloacae (9), Serratia marcescens (7), Citrobacter koseri (6), Enterobacter aerogenes (5), Citrobacter freundii (4), Morganella morganii (4), Klebsiella oxytoca (3), Proteus vulgaris (3), Citrobacter farmeri (2), Pantoea agglomerans (2), Serratia liquefaciens (2), Citrobacter braakii (1), Enterobacter gergoviae (1), Kluyvera sp. (1), Providencia rettgeri (1) and Raoultella ornithinolytica (1). Twenty-seven (9.6%) were ESBL producers, 16 (5.7%) were inducible AmpC b-lactamase producers and 8 (2.8%) were derepressed AmpC b-lactamase producers.
Identification and susceptibility testing were performed on overnight cultures using the BD Phoenix TM AP instrument (automated nephelometry) and the BD Phoenix TM Automated Microbiology System (instrument version 5.15A, software version 6.01A/ V5.15A) with Gram-negative Phoenix panels (NMIC-84). Temocillin MICs were also determined by BMD in cation-adjusted Mueller-
